Recombinant vaccines for the prevention of human papillomavirus infection and cervical cancer

Experimental and Molecular Pathology

Volumn 86, Issue 3, 2009, Pages 224-233

  Palmer, Kenneth E ^a,b,c   Jenson, A Bennett ^a   Kouokam, J Calvin ^a,b,c   Lasnik, Amanda B ^a,b,c   Ghim, Shin je ^a,b  

^a UNIVERSITY OF LOUISVILLE SCHOOL OF MEDICINE   (United States)

^b University of Louisville School of Medicine   (United States)

^c Owensboro Cancer Research Program   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PLACEBO; UNCLASSIFIED DRUG; WART VIRUS VACCINE; WART VIRUS VACCINE L1; WART VIRUS VACCINE L2;

CANCER PREVENTION; CLINICAL TRIAL; CONDYLOMA ACUMINATUM; CYTOLOGY; DRUG EFFICACY; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 16; MOLECULAR BIOLOGY; NONHUMAN; PROPHYLAXIS; REVIEW; TUMOR IMMUNITY; UTERINE CERVIX CANCER; VACCINATION; VIRUS IMMUNITY; VIRUS INFECTION; VIRUS LIKE AGENT; WART VIRUS;

ANTIGENS, VIRAL; FEMALE; HUMAN PAPILLOMAVIRUS 16; HUMAN PAPILLOMAVIRUS 18; HUMANS; PAPILLOMAVIRUS INFECTIONS; PAPILLOMAVIRUS VACCINES; UTERINE CERVICAL NEOPLASMS; VACCINES, SYNTHETIC;

HUMAN PAPILLOMAVIRUS; PAPILLOMAVIRIDAE;

EID: 67349271268     PISSN: 00144800     EISSN: 10960945     Source Type: Journal    
DOI: 10.1016/j.yexmp.2009.01.009     Document Type: Review

References (105)

1. Alphs H.H., Gambhira R., Karanam B., Roberts J.N., Jagu S., Schiller J.T., Zeng W., Jackson D.C., and Roden R.B. Protection against heterologous human PV challenge by a synthetic lipopeptide vaccine containing a broadly cross-neutralizing epitope of L2. Proc. Natl. Acad. Sci. USA 105 15 (2008) 5850-5855
2. Baseman J.G., and Koutsky L.A. The epidemiology of human PV infections. J. Clin. Virol. 32 Suppl 1 (2005) S16-S24
3. Baud D., Benyacoub J., Revaz V., Kok M., Ponci F., Bobst M., Curtiss III R., De Grandi P., and Nardelli-Haefliger D. Immunogenicity against human PV type 16 virus-like particles is strongly enhanced by the PhoPc phenotype in Salmonella enterica serovar Typhimurium. Infect. Immun. 72 2 (2004) 750-756
4. Baud D., Ponci F., Bobst M., De Grandi P., and Nardelli-Haefliger D. Improved efficiency of a Salmonella-based vaccine against human PV type 16 virus-like particles achieved by using a codon-optimized version of L1. J. Virol. 78 23 (2004) 12901-12909
5. Belnap D.M., Olson N.H., Cladel N.M., Newcomb W.W., Brown J.C., Kreider J.W., Christensen N.D., and Baker T.S. Conserved features in PV and polyomavirus capsids. J. Mol. Biol. 259 2 (1996) 249-263
6. Berg M., Difatta J., Hoiczyk E., Schlegel R., and Ketner G. Viable adenovirus vaccine prototypes: high-level production of a PV capsid antigen from the major late transcriptional unit. Proc. Natl. Acad. Sci. USA 102 12 (2005) 4590-4595
7. Berg M., Gambhira R., Siracusa M., Hoiczyk E., Roden R., and Ketner G. HPV16 L1 capsid protein expressed from viable adenovirus recombinants elicits neutralizing antibody in mice. Vaccine 25 17 (2007) 3501-3510
8. Biemelt S., Sonnewald U., Galmbacher P., Willmitzer L., and Muller M. Production of human PV type 16 virus-like particles in transgenic plants. J. Virol. 77 17 (2003) 9211-9220
9. Bishop B., Dasgupta J., Klein M., Garcea R.L., Christensen N.D., Zhao R., and Chen X.S. Crystal structures of four types of human PV L1 capsid proteins: understanding the specificity of neutralizing monoclonal antibodies. J. Biol. Chem. 282 43 (2007) 31803-31811
10. Bonnez W. Human PV vaccine-recent results and future developments. Curr. Opin. Pharmacol. 7 5 (2007) 470-477
11. Bosch F.X., Burchell A.N., Schiffman M., Giuliano A.R., de Sanjose S., Bruni L., Tortolero-Luna G., Kjaer S.K., and Munoz N. Epidemiology and natural history of human PV infections and type-specific implications in cervical neoplasia. Vaccine 26 Suppl 10 (2008) K1-K16
12. Bottley G., Watherston O.G., Hiew Y.L., Norrild B., Cook G.P., and Blair G.E. High-risk human PV E7 expression reduces cell-surface MHC class I molecules and increases susceptibility to natural killer cells. Oncogene 27 12 (2008) 1794-1799
13. Buchbinder S.P., Mehrotra D.V., Duerr A., Fitzgerald D.W., Mogg R., Li D., Gilbert P.B., Lama J.R., Marmor M., Del Rio C., McElrath M.J., Casimiro D.R., Gottesdiener K.M., Chodakewitz J.A., Corey L., and Robertson M.N. Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): a double-blind, randomised, placebo-controlled, test-of-concept trial. Lancet 372 9653 (2008) 1881-1893
14. Buck C.B., and Thompson C.D. Production of PV-based gene transfer vectors. Curr. Protoc. Cell Biol. (2007) Chapter 26, Unit 26 1
15. Buck C.B., Pastrana D.V., Lowy D.R., and Schiller J.T. Efficient intracellular assembly of papillomaviral vectors. J. Virol. 78 2 (2004) 751-757
16. Buck C.B., Pastrana D.V., Lowy D.R., and Schiller J.T. Generation of HPV pseudovirions using transfection and their use in neutralization assays. Methods Mol. Med. 119 (2005) 445-462
17. Buck C.B., Thompson C.D., Pang Y.Y., Lowy D.R., and Schiller J.T. Maturation of PV capsids. J. Virol. 79 5 (2005) 2839-2846
18. Buck C.B., Cheng N., Thompson C.D., Lowy D.R., Steven A.C., Schiller J.T., and Trus B.L. Arrangement of L2 within the PV capsid. J. Virol. 82 11 (2008) 5190-5197
19. Campo M.S., O'Neil B.W., Grindlay G.J., Curtis F., Knowles G., and Chandrachud L. A peptide encoding a B-cell epitope from the N-terminus of the capsid protein L2 of bovine PV-4 prevents disease. Virology 234 2 (1997) 261-266
20. Carter J.J., Wipf G.C., Benki S.F., Christensen N.D., and Galloway D.A. Identification of a human PV type 16-specific epitope on the C-terminal arm of the major capsid protein L1. J. Virol. 77 21 (2003) 11625-11632
21. Chandrachud L.M., Grindlay G.J., McGarvie G.M., O'Neil B.W., Wagner E.R., Jarrett W.F., and Campo M.S. Vaccination of cattle with the N-terminus of L2 is necessary and sufficient for preventing infection by bovine PV-4. Virology 211 1 (1995) 204-208
22. Chen Y., Ghim S.-J., Jenson A.B., and Schlegel R. Mutant canine oral PV L1 capsid proteins which form virus-like particles but lack native conformational epitopes. J. Gen. Virol. 79 (1998) 2137-2146
23. Chen X.S., Garcea R.L., Goldberg I., Casini G., and Harrison S.C. Structure of small virus-like particles assembled from the L1 protein of human PV 16. Mol. Cell 5 3 (2000) 557-567
24. Christensen N.D., Kreider J.W., Kan N.C., and DiAngelo S.L. The open reading frame L2 of cottontail rabbit PV contains antibody-inducing neutralizing epitopes. Virology 181 2 (1991) 572-579
25. Culp T.D., and Christensen N.D. Kinetics of in vitro adsorption and entry of PV virions. Virology 319 1 (2004) 152-161
26. Culp T.D., Spatz C.M., Reed C.A., and Christensen N.D. Binding and neutralization efficiencies of monoclonal antibodies, Fab fragments, and scFv specific for L1 epitopes on the capsid of infectious HPV particles. Virology 361 2 (2007) 435-446
27. Davidson E.J., Faulkner R.L., Sehr P., Pawlita M., Smyth L.J., Burt D.J., Tomlinson A.E., Hickling J., Kitchener H.C., and Stern P.L. Effect of TA-CIN (HPV 16 L2E6E7) booster immunisation in vulval intraepithelial neoplasia patients previously vaccinated with TA-HPV (vaccinia virus encoding HPV 16/18 E6E7). Vaccine 22 21-22 (2004) 2722-2729
28. Day P.M., Roden R.B., Lowy D.R., and Schiller J.T. The PV minor capsid protein, L2, induces localization of the major capsid protein, L1, and the viral transcription/replication protein, E2, to PML oncogenic domains. J. Virol. 72 1 (1998) 142-150
29. Day P.M., Thompson C.D., Buck C.B., Pang Y.Y., Lowy D.R., and Schiller J.T. Neutralization of human PV with monoclonal antibodies reveals different mechanisms of inhibition. J. Virol. 81 16 (2007) 8784-8792
30. Day P.M., Gambhira R., Roden R.B., Lowy D.R., and Schiller J.T. Mechanisms of human PV type 16 neutralization by l2 cross-neutralizing and l1 type-specific antibodies. J. Virol. 82 9 (2008) 4638-4646
31. Day P.M., Lowy D.R., and Schiller J.T. Heparan sulfate-independent cell binding and infection with furin-precleaved PV capsids. J. Virol. 82 24 (2008) 12565-12568
32. de Villiers E.M., Fauquet C., Broker T.R., Bernard H.U., and zur Hausen H. Classification of PVs. Virology 324 1 (2004) 17-27
33. DeVoti J.A., Rosenthal D.W., Wu R., Abramson A.L., Steinberg B.M., and Bonagura V.R. Immune dysregulation and tumor-associated gene changes in recurrent respiratory papillomatosis: a paired microarray analysis. Mol. Med. 14 9-10 (2008) 608-617
34. Echchannaoui H., Bianchi M., Baud D., Bobst M., Stehle J.C., and Nardelli-Haefliger D. Intravaginal immunization of mice with recombinant Salmonella enterica serovar Typhimurium expressing human PV type 16 antigens as a potential route of vaccination against cervical cancer. Infect. Immun. 76 5 (2008) 1940-1951
35. Fernandez-San Millan A., Ortigosa S.M., Hervas-Stubbs S., Corral-Martinez P., Segui-Simarro J.M., Gaetan J., Coursaget P., and Veramendi J. Human PV L1 protein expressed in tobacco chloroplasts self-assembles into virus-like particles that are highly immunogenic. Plant Biotechnol. J. 6 5 (2008) 427-441
36. Florin L., Becker K.A., Lambert C., Nowak T., Sapp C., Strand D., Streeck R.E., and Sapp M. Identification of a dynein interacting domain in the PV minor capsid protein l2. J. Virol. 80 13 (2006) 6691-6696
37. Fraillery D., Baud D., Pang S.Y., Schiller J., Bobst M., Zosso N., Ponci F., and Nardelli-Haefliger D. Salmonella enterica serovar Typhi Ty21a expressing human PV type 16 L1 as a potential live vaccine against cervical cancer and typhoid fever. Clin. Vaccine Immunol. 14 10 (2007) 1285-1295
38. Gambhira R., Jagu S., Karanam B., Gravitt P.E., Culp T.D., Christensen N.D., and Roden R.B. Protection of rabbits against challenge with rabbit PVs by immunization with the N terminus of human PV type 16 minor capsid antigen L2. J. Virol. 81 21 (2007) 11585-11592
39. Gambhira R., Karanam B., Jagu S., Roberts J.N., Buck C.B., Bossis I., Alphs H., Culp T., Christensen N.D., and Roden R.B. A protective and broadly cross-neutralizing epitope of human PV L2. J. Virol. 81 24 (2007) 13927-13931
40. Gaukroger J.M., Chandrachud L.M., O'Neil B.W., Grindlay G.J., Knowles G., and Campo M.S. Vaccination of cattle with bovine PV type 4 L2 elicits the production of virus-neutralizing antibodies. J. Gen. Virol. 77 Pt 7 (1996) 1577-1583
41. Ghim S., Christensen N.D., Kreider J.W., and Jenson A.B. Comparison of neutralization of BPV-1 infection of C127 cells and bovine fetal skin xenografts. Int. J. Cancer 49 2 (1991) 285-289
42. Ghim S.J., Jenson A.B., and Schlegel R. HPV-1 L1 protein expressed in cos cells displays conformational epitopes found on intact virions. Virology 190 1 (1992) 548-552
43. Ghim S., Newsome J., Bell J., Sundberg J.P., Schlegel R., and Jenson A.B. Spontaneously regressing oral papillomas induce systemic antibodies that neutralize canine oral PV. Exp. Mol. Pathol. 68 3 (2000) 147-151
44. Ghim S., Basu P.S., and Jenson A.B. Cervical cancer, etiology, pathogenesis treatment and future vaccines. Asian Pacific J. Cancer Prev. 3 (2002) 207-214
45. Giroglou T., Florin L., Schafer F., Streeck R.E., and Sapp M. Human PV infection requires cell surface heparan sulfate. J. Virol. 75 3 (2001) 1565-1570
46. Govan V.A., Christensen N.D., Berkower C., Jacobs Jr. W.R., and Williamson A.L. Immunisation with recombinant BCG expressing the cottontail rabbit PV (CRPV) L1 gene provides protection from CRPV challenge. Vaccine 24 12 (2006) 2087-2093
47. Harper D.M., Franco E.L., Wheeler C.M., Moscicki A.B., Romanowski B., Roteli-Martins C.M., Jenkins D., Schuind A., Costa Clemens S.A., Dubin G., and HPV Vaccine Study group. Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial. Lancet 367 9518 (2006) 1247-1255
48. Hasan U.A., Bates E., Takeshita F., Biliato A., Accardi R., Bouvard V., Mansour M., Vincent I., Gissmann L., Iftner T., Sideri M., Stubenrauch F., and Tommasino M. TLR9 expression and function is abolished by the cervical cancer-associated human PV type 16. J. Immunol. 178 5 (2007) 3186-3197
49. Herdman M.T., Pett M.R., Roberts I., Alazawi W.O., Teschendorff A.E., Zhang X.Y., Stanley M.A., and Coleman N. Interferon-beta treatment of cervical keratinocytes naturally infected with human PV 16 episomes promotes rapid reduction in episome numbers and emergence of latent integrants. Carcinogenesis 27 11 (2006) 2341-2353
50. Hines J.F., Ghim S.J., Christensen N.D., Kreider J.W., Barnes W.A., Schlegel R., and Jenson A.B. Role of conformational epitopes expressed by human PV major capsid proteins in the serologic detection of infection and prophylactic vaccination. Gynecol. Oncol. 55 1 (1994) 13-20
51. Hofmann K.J., Cook J.C., Joyce J.G., Brown D.R., Schultz L.D., George H.A., Rosolowsky M., Fife K.H., and Jansen K.U. Sequence determination of human PV type 6a and assembly of virus-like particles in Saccharomyces cerevisiae. Virology 209 2 (1995) 506-518
52. Jansen K.U., Rosolowsky M., Schultz L.D., Markus H.Z., Cook J.C., Donnelly J.J., Martinez D., Ellis R.W., and Shaw A.R. Vaccination with yeast-expressed cottontail rabbit PV (CRPV) virus-like particles protects rabbits from CRPV-induced papilloma formation. Vaccine 13 16 (1995) 1509-1514
53. Johnson K.M., Kines R.C., Roberts J.N., Lowy D.R., Schiller J.T., and Day P.M. The role of heparan sulfate in HPV attachment and infection of the murine female genital tract. J Virol. 83 5 (2008) 2067-2074
54. Joura E.A., Kjaer S.K., Wheeler C.M., Sigurdsson K., Iversen O.E., Hernandez-Avila M., Perez G., Brown D.R., Koutsky L.A., Tay E.H., Garcia P., Ault K.A., Garland S.M., Leodolter S., Olsson S.E., Tang G.W., Ferris D.G., Paavonen J., Lehtinen M., Steben M., Bosch X., Dillner J., Kurman R.J., Majewski S., Munoz N., Myers E.R., Villa L.L., Taddeo F.J., Roberts C., Tadesse A., Bryan J., Lupinacci L.C., Giacoletti K.E., Lu S., Vuocolo S., Hesley T.M., Haupt R.M., and Barr E. HPV antibody levels and clinical efficacy following administration of a prophylactic quadrivalent HPV vaccine. Vaccine 26 52 (2008) 6844-6851
55. Kamper N., Day P.M., Nowak T., Selinka H.C., Florin L., Bolscher J., Hilbig L., Schiller J.T., and Sapp M. A membrane-destabilizing peptide in capsid protein L2 is required for egress of PV genomes from endosomes. J. Virol. 80 2 (2006) 759-768
56. Kanda T., and Kondo K. Development of an HPV vaccine for a broad spectrum of high-risk types. Hum. Vaccin. 5 1 (2008) 43-45
57. Karanam B., Gambhira R., Peng S., Jagu S., Kim D.J., Ketner G.W., Stern P.L., Adams R.J., and Roden R.B. Vaccination with HPV16 L2E6E7 fusion protein in GPI-0100 adjuvant elicits protective humoral and cell-mediated immunity. Vaccine 27 7 (2008) 1040-1049
58. Kawana K., Matsumoto K., Yoshikawa H., Taketani Y., Kawana T., Yoshiike K., and Kanda T. A surface immunodeterminant of human PV type 16 minor capsid protein L2. Virology 245 2 (1998) 353-359
59. Kawana K., Yoshikawa H., Taketani Y., Yoshiike K., and Kanda T. Common neutralization epitope in minor capsid protein L2 of human PV types 16 and 6. J. Virol. 73 7 (1999) 6188-6190
60. Kirnbauer R., Booy F., Cheng N., Lowy D.R., and Schiller J.T. PV L1 major capsid protein self-assembles into virus-like particles that are highly immunogenic. Proc. Natl. Acad. Sci. USA 89 24 (1992) 12180-12184
61. Knappe M., Bodevin S., Selinka H.C., Spillmann D., Streeck R.E., Chen X.S., Lindahl U., and Sapp M. Surface-exposed amino acid residues of HPV16 L1 protein mediating interaction with cell surface heparan sulfate. J. Biol. Chem. 282 38 (2007) 27913-27922
62. Knowles G., Grindlay G.J., Campo M.S., Chandrachud L.M., and O'Neil B.W. Linear B-cell epitopes in the N-terminus of L2 of bovine PV type 4. Res. Vet. Sci. 62 3 (1997) 289-291
63. Kohl T., Hitzeroth I.I., Stewart D., Varsani A., Govan V.A., Christensen N.D., Williamson A.L., and Rybicki E.P. Plant-produced cottontail rabbit PV L1 protein protects against tumor challenge: a proof-of-concept study. Clin. Vaccine Immunol. 13 8 (2006) 845-853
64. Kohl T.O., Hitzeroth I.I., Christensen N.D., and Rybicki E.P. Expression of HPV-11 L1 protein in transgenic Arabidopsis thaliana and Nicotiana tabacum. BMC Biotechnol. 7 (2007) 56
65. Kondo K., Ochi H., Matsumoto T., Yoshikawa H., and Kanda T. Modification of human PV-like particle vaccine by insertion of the cross-reactive L2-epitopes. J. Med. Virol. 80 5 (2008) 841-846
66. Koutsky L.A., Ault K.A., Wheeler C.M., Brown D.R., Barr E., Alvarez F.B., Chiacchierini L.M., and Jansen K.U. A controlled trial of a human PV type 16 vaccine. N. Engl. J. Med. 347 21 (2002) 1645-1651
67. Lenzi P., Scotti N., Alagna F., Tornesello M.L., Pompa A., Vitale A., De Stradis A., Monti L., Grillo S., Buonaguro F.M., Maliga P., and Cardi T. Translational fusion of chloroplast-expressed human PV type 16 L1 capsid protein enhances antigen accumulation in transplastomic tobacco. Transgenic Res. 17 6 (2008) 1091-1102
68. Lin Y.L., Borenstein L.A., Selvakumar R., Ahmed R., and Wettstein F.O. Effective vaccination against papilloma development by immunization with L1 or L2 structural protein of cottontail rabbit PV. Virology 187 2 (1992) 612-619
69. Lin Y.L., Borenstein L.A., Ahmed R., and Wettstein F.O. Cottontail rabbit PV L1 protein-based vaccines: protection is achieved only with a full-length, nondenatured product. J. Virol. 67 7 (1993) 4154-4162
70. Maclean J., Koekemoer M., Olivier A.J., Stewart D., Hitzeroth I.I., Rademacher T., Fischer R., Williamson A.L., and Rybicki E.P. Optimization of human PV type 16 (HPV-16) L1 expression in plants: comparison of the suitability of different HPV-16 L1 gene variants and different cell-compartment localization. J. Gen. Virol. 88 Pt 5 (2007) 1460-1469
71. Marais D., Carrara H., Kay P., Ramjee G., Allan B., and Williamson A.L. The impact of the use of COL-1492, a nonoxynol-9 vaginal gel, on the presence of cervical human PV in female sex workers. Virus Res. 121 2 (2006) 220-222
72. McNeil C. Who invented the VLP cervical cancer vaccines?. J. Natl. Cancer Inst. 98 7 (2006) 433
73. Paavonen J., Jenkins D., Bosch F.X., Naud P., Salmeron J., Wheeler C.M., Chow S.N., Apter D.L., Kitchener H.C., Castellsague X., de Carvalho N.S., Skinner S.R., Harper D.M., Hedrick J.A., Jaisamrarn U., Limson G.A., Dionne M., Quint W., Spiessens B., Peeters P., Struyf F., Wieting S.L., Lehtinen M.O., and Dubin G. Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human PV types 16 and 18 in young women: an interim analysis of a phase III double-blind, randomised controlled trial. Lancet 369 9580 (2007) 2161-2170
74. Palmer K.E., Benko A., Doucette S.A., Cameron T.I., Foster T., Hanley K.M., McCormick A.A., McCulloch M., Pogue G.P., Smith M.L., and Christensen N.D. Protection of rabbits against cutaneous PV infection using recombinant tobacco mosaic virus containing L2 capsid epitopes. Vaccine 24 26 (2006) 5516-5525
75. Pastrana D.V., Buck C.B., Pang Y.Y., Thompson C.D., Castle P.E., FitzGerald P.C., Kruger Kjaer S., Lowy D.R., and Schiller J.T. Reactivity of human sera in a sensitive, high-throughput pseudovirus-based PV neutralization assay for HPV16 and HPV18. Virology 321 2 (2004) 205-216
76. Pastrana D.V., Gambhira R., Buck C.B., Pang Y.Y., Thompson C.D., Culp T.D., Christensen N.D., Lowy D.R., Schiller J.T., and Roden R.B. Cross-neutralization of cutaneous and mucosal PV types with anti-sera to the amino terminus of L2. Virology 337 2 (2005) 365-372
77. Reuter J.D., Vivas-Gonzalez B.E., Gomez D., Wilson J.H., Brandsma J.L., Greenstone H.L., Rose J.K., and Roberts A. Intranasal vaccination with a recombinant vesicular stomatitis virus expressing cottontail rabbit PV L1 protein provides complete protection against PV-induced disease. J. Virol. 76 17 (2002) 8900-8909
78. Richards R.M., Lowy D.R., Schiller J.T., and Day P.M. Cleavage of the PV minor capsid protein, L2, at a furin consensus site is necessary for infection. Proc. Natl. Acad. Sci. USA 103 5 (2006) 1522-1527
79. Roberts A., Reuter J.D., Wilson J.H., Baldwin S., and Rose J.K. Complete protection from PV challenge after a single vaccination with a vesicular stomatitis virus vector expressing high levels of L1 protein. J. Virol. 78 6 (2004) 3196-3199
80. Roberts J.N., Buck C.B., Thompson C.D., Kines R., Bernardo M., Choyke P.L., Lowy D.R., and Schiller J.T. Genital transmission of HPV in a mouse model is potentiated by nonoxynol-9 and inhibited by carrageenan. Nat. Med. 13 7 (2007) 857-861
81. Roden R.B., Yutzy W.H.T., Fallon R., Inglis S., Lowy D.R., and Schiller J.T. Minor capsid protein of human genital PVs contains subdominant, cross-neutralizing epitopes. Virology 270 2 (2000) 254-257
82. Rollman E., Arnheim L., Collier B., Oberg D., Hall H., Klingstrom J., Dillner J., Pastrana D.V., Buck C.B., Hinkula J., Wahren B., and Schwartz S. HPV-16 L1 genes with inactivated negative RNA elements induce potent immune responses. Virology 322 1 (2004) 182-189
83. Rose R.C., Bonnez W., Reichman R.C., and Garcea R.L. Expression of human PV type 11 L1 protein in insect cells: in vivo and in vitro assembly of viruslike particles. J. Virol. 67 4 (1993) 1936-1944
84. Rowson K.E., and Mahy B.W. Human papova (wart) virus. Bacteriol. Rev. 31 2 (1967) 110-131
85. Rybicki E.P. Plant-produced vaccines: promise and reality. Drug Discov. Today 14 1-2 (2008) 16-24
86. Schiffman M., Castle P.E., Jeronimo J., Rodriguez A.C., and Wacholder S. Human PV and cervical cancer. Lancet 370 9590 (2007) 890-907
87. Schiller J.T., Castellsague X., Villa L.L., and Hildesheim A. An update of prophylactic human PV L1 virus-like particle vaccine clinical trial results. Vaccine 26 Suppl 10 (2008) K53-K61
88. Selinka H.C., Giroglou T., and Sapp M. Analysis of the infectious entry pathway of human PV type 33 pseudovirions. Virology 299 2 (2002) 279-287
89. Selinka H.C., Giroglou T., Nowak T., Christensen N.D., and Sapp M. Further evidence that PV capsids exist in two distinct conformations. J. Virol. 77 24 (2003) 12961-12967
90. Selinka H.C., Florin L., Patel H.D., Freitag K., Schmidtke M., Makarov V.A., and Sapp M. Inhibition of transfer to secondary receptors by heparan sulfate-binding drug or antibody induces noninfectious uptake of human PV. J. Virol. 81 20 (2007) 10970-10980
91. Slupetzky K., Gambhira R., Culp T.D., Shafti-Keramat S., Schellenbacher C., Christensen N.D., Roden R.B., and Kirnbauer R. A PV-like particle (VLP) vaccine displaying HPV16 L2 epitopes induces cross-neutralizing antibodies to HPV11. Vaccine 25 11 (2007) 2001-2010
92. ® cross-neutralize HPV 45 pseudovirions. Hum. Vaccin. 3 4 (2007) 109-115
93. Smyth L.J., Van Poelgeest M.I., Davidson E.J., Kwappenberg K.M., Burt D., Sehr P., Pawlita M., Man S., Hickling J.K., Fiander A.N., Tristram A., Kitchener H.C., Offringa R., Stern P.L., and Van Der Burg S.H. Immunological responses in women with human PV type 16 (HPV-16)-associated anogenital intraepithelial neoplasia induced by heterologous prime-boost HPV-16 oncogene vaccination. Clin. Cancer Res. 10 9 (2004) 2954-2961
94. Stanley M. Immune responses to human PV. Vaccine 24 Suppl 1 (2006) S16-S22
95. Stanley M.A., Pett M.R., and Coleman N. HPV: from infection to cancer. Biochem. Soc. Trans. 35 Pt 6 (2007) 1456-1460
96. Stanley M., Gissmann L., and Nardelli-Haefliger D. Immunobiology of human PV infection and vaccination - implications for second generation vaccines. Vaccine 26 Suppl 10 (2008) K62-K67
97. Suzich J.A., Ghim S.J., Palmer-Hill F.J., White W.I., Tamura J.K., Bell J.A., Newsome J.A., Jenson A.B., and Schlegel R. Systemic immunization with PV L1 protein completely prevents the development of viral mucosal papillomas. Proc. Natl. Acad. Sci. USA 92 25 (1995) 11553-11557
98. Thones N., Herreiner A., Schadlich L., Piuko K., and Muller M. A direct comparison of human PV type 16 L1 particles reveals a lower immunogenicity of capsomeres than viruslike particles with respect to the induced antibody response. J. Virol. 82 11 (2008) 5472-5485
99. Trus B.L., Roden R.B., Greenstone H.L., Vrhel M., Schiller J.T., and Booy F.P. Novel structural features of bovine PV capsid revealed by a three-dimensional reconstruction to 9 A resolution. Nat. Struct. Biol. 4 5 (1997) 413-420
100. van der Burg S.H., Kwappenberg K.M., O'Neill T., Brandt R.M., Melief C.J., Hickling J.K., and Offringa R. Pre-clinical safety and efficacy of TA-CIN, a recombinant HPV16 L2E6E7 fusion protein vaccine, in homologous and heterologous prime-boost regimens. Vaccine 19 27 (2001) 3652-3660
101. Warzecha H., Mason H.S., Lane C., Tryggvesson A., Rybicki E., Williamson A.L., Clements J.D., and Rose R.C. Oral immunogenicity of human PV-like particles expressed in potato. J. Virol. 77 16 (2003) 8702-8711
102. Yang R., Day P.M., Yutzy W.H.T., Lin K.Y., Hung C.F., and Roden R.B. Cell surface-binding motifs of L2 that facilitate PV infection. J. Virol. 77 6 (2003) 3531-3541
103. Yuan H., Estes P.A., Chen Y., Newsome J., Olcese V.A., Garcea R.L., and Schlegel R. Immunization with a pentameric L1 fusion protein protects against PV infection. J Virol 75 17 (2001) 7848-7853
104. Zhou J., Sun X.Y., Stenzel D.J., and Frazer I.H. Expression of vaccinia recombinant HPV 16 L1 and L2 ORF proteins in epithelial cells is sufficient for assembly of HPV virion-like particles. Virology 185 1 (1991) 251-257
105. Zur Hausen H. Papillomaviruses in the causation of human cancers - a brief historical account. Virology (2009) (Electronic publication, Jan 7, 2009)